Market Place
Sourcing Support
Jaguar Health Reports Third Quarter 2024 Financial Results
13 Nov 2024 //
ACCESSWIRE
Jaguar Health to Hold Q3 2024 Financial Webcast on Nov 13
11 Nov 2024 //
ACCESSWIRE
FDA Approves Canalevia for Chemotherapy-Induced Diarrhea in Dogs
06 Nov 2024 //
ACCESSWIRE
Jaguar`s Crofelemer Shows Positive IBS-D Results at ACG Meeting
29 Oct 2024 //
ACCESSWIRE
Jaguar Health Launches FDA-Approved Gelclair In The U.S.
16 Oct 2024 //
ACCESSWIRE
Jaguar Announces Inducement Grants Under Nasdaq Rule
11 Oct 2024 //
ACCESSWIRE
Magdalena Biosciences To Present At BIO Investor Forum Oct 16
10 Oct 2024 //
ACCESSWIRE
Jaguar Health Submits Abstract For Cancer Diarrhea Study
08 Oct 2024 //
ACCESSWIRE
Jaguar Health Reports Positive Phase 3 Results For Crofelemer
01 Oct 2024 //
ACCESSWIRE
Jaguar Health To Present At MedInvest Conference
16 Sep 2024 //
ACCESSWIRE
Jaguar Health Appoints Veteran To Lead Oncology, HIV Sales
10 Sep 2024 //
ACCESSWIRE
Jaguar Health To Present At H.C. Wainwright Conference
06 Sep 2024 //
ACCESSWIRE
Jaguar Health Gets New Hong Kong Patent For Short Bowel Syndrome Treatment
19 Aug 2024 //
ACCESSWIRE
Jaguar Health To Hold Investor Webcast On Q2 Earnings And Trial Results
12 Aug 2024 //
ACCESSWIRE
Jaguar Health To Explore Crofelemer For Breast And Lung Cancer
05 Aug 2024 //
ACCESSWIRE
Napo Pharma Gets EU Patent For Crofelemer In CDD-Related Diarrhea
02 Aug 2024 //
PHARMABIZ
Jaguar Health`s Elisabetsky To Speak On Plant-Based Schizophrenia Meds
02 Aug 2024 //
ACCESSWIRE
Jaguar Health`s Crofelemer Shows Positive Results For IBS-D Diarrhea
01 Aug 2024 //
ACCESSWIRE
Jaguar Health Receives New European Patent For CDD Treatment
31 Jul 2024 //
ACCESSWIRE
Jaguar Health To Report Phase 3 Crofelemer Results On July 23
18 Jul 2024 //
ACCESSWIRE
Jaguar Health Strengthens IP With New Patents For SBS And CDD Treatments
08 Jul 2024 //
ACCESSWIRE
Jaguar Health Regains Compliance with Nasdaq`s Bid Price Requirement
26 Jun 2024 //
ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting
21 Jun 2024 //
ACCESSWIRE
Jaguar Health To Report Phase 3 OnTarget Trial Results By July 23
12 Jun 2024 //
ACCESSWIRE
Jaguar Health Reports New Employee Inducement Grant
06 Jun 2024 //
ACCESSWIRE
Jaguar Out-Licenses Botanical Candidate For Schizophrenia To JV
29 May 2024 //
ACCESSWIRE
Jaguar Health: Positive Crofelemer Trial Results For Functional Diarrhea
28 May 2024 //
ACCESSWIRE
Jaguar Gelclair Asco Launch: Oral Mucositis Product Exhibit Debut
23 May 2024 //
ACCESSWIRE
Jaguar Health, Inc. Announces Reverse Stock Split
17 May 2024 //
ACCESSWIRE
Jaguar Health Reports First Quarter 2024 Financial Results
14 May 2024 //
ACCESSWIRE
Jaguar Health Webcast On Q1 2024 Financials, Corporate Update On May 14
13 May 2024 //
ACCESSWIRE
Jaguar MVID, SBS Trial Applications In Europe
09 May 2024 //
ACCESSWIRE
Jaguar Health To Host Webcast On Q1 2024 Financials, Updates
08 May 2024 //
ACCESSWIRE
Crofelemer receives FDA conditional approval for chemotherapy-induced diarrhea
06 May 2024 //
ACCESSWIRE
Napo Sponsors MVID Panel at Pedia GI Conference in Abu Dhabi
29 Apr 2024 //
ACCESSWIRE
Jaguar Health Appoints Biopharma Veteran For In-Licensing
18 Apr 2024 //
ACCESSWIRE
Jaguar Licenses FDA Oral Mucositis Product, Enters Cancer Supportive Care Market
16 Apr 2024 //
ACCESSWIRE
Jaguar Health Shareholder Proposals Approved
09 Apr 2024 //
ACCESSWIRE
Jaguar Health Granted Extension to Regain Compliance with Nasdaq`s Bid Price
08 Apr 2024 //
ACCESSWIRE
Jaguar Health Appoints European Pharmaceutical Industry Leader as a President
02 Apr 2024 //
ACCESSWIRE
Jaguar Health Reports 2023 Financial Results
01 Apr 2024 //
ACCESSWIRE
JH to Hold Investor Webcast at 8:30 AM Eastern Regarding Q4 2023 Financials
27 Mar 2024 //
ACCESSWIRE
GEN to Commercialize Jaguar Health`s Crofelemer and Invest $2M in Stock
20 Mar 2024 //
ACCESSWIRE
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
23 Feb 2024 //
ACCESSWIRE
Jaguar Announces FDA Agrees with Trial Protocol for Approval of Canalevia-CA1
15 Feb 2024 //
ACCESSWIRE
Jaguar Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
14 Feb 2024 //
ACCESSWIRE
Jaguar Announces Submission of ODD Application for Crofelemer
12 Feb 2024 //
ACCESSWIRE
Dog Study Published in PLOS ONE Shows Results for Use of Jaguar’s Crofelemer
25 Jan 2024 //
ACCESSWIRE
Jaguar Announces New Employee Inducement Grant Under Nasdaq Rule 5635(c)(4)
05 Jan 2024 //
ACCESSWIRE
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in CDDs
04 Jan 2024 //
ACCESSWIRE
MASCC Webinar on GI Toxicities Made Possible by Grant From Napo
07 Dec 2023 //
ACCESSWIRE
FDA Approves Renewal of Canalevia-CA1
04 Dec 2023 //
ACCESSWIRE
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis
21 Nov 2023 //
ACCESSWIRE
Jaguar Health Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
ACCESSWIRE
Jaguar Announces Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 Nov 2023 //
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Regarding Q3 2023 Financials Updates
08 Nov 2023 //
ACCESSWIRE
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance
08 Nov 2023 //
ACCESSWIRE
Jaguar Health to Host Educational Webinar on Rare Intestinal Failure Diseases
07 Nov 2023 //
ACCESSWIRE
Jaguar Health Enters Agreement with Quadri Pharmaceuticals Store
02 Nov 2023 //
ACCESSWIRE
